Ticker

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA - Get Free Report) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totaling 16,112 shares, a decrease of 58.7% from the March 31st total of 38,967 shares. Based on an average daily trading volume, of 30,779

BOULDER, CO / ACCESS Newswire / April 24, 2026 / Sonoma Pharmaceuticals, Inc. (the "Company" or "Sonoma Pharmaceuticals") (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the pricing of its public offering made on a firm commitment basis with gross proceeds to the Company expected to be approximately $4.0 million, before deducting fees and other expenses payable by…

Sonoma Pharmaceuticals jumps over 16% in after-hours trading following the U.S. retail launch of its burn relief hydrogel in CVS and Walmart stores.

BOULDER, CO / ACCESS Newswire / March 24, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the U.S. retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart stores nationwide. The hydrogel is indicated for the management of minor burns and skin irritations.

BOULDER, CO / ACCESS Newswire / March 18, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced the launch of Aquanil® AD, a hypochlorous acid…